Pfizer reject enters Phase III for brain cancer
This article was originally published in Scrip
Celldex Therapeutics has begun Phase III testing of rindopepimut in glioblastoma. Celldex regained the rights to rindopepimut, an immunotherapeutic vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), last year after Pfizer informed Celldex that the rindopepimut programme was no longer a strategic priority for Pfizer.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.